You are here

Approvals, Launches, and New Indications

Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients
Statistically Significant Improvement in Excessive Daytime Sleepiness
100% of Responders Maintained Response for 12 Months or More
Showed Significant Improvement in Metastasis-Free Survival
May Be Used in Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Polyangiitis
Otezla Approved for Behçet’s Syndrome
For Diabetic Neuropathic Pain, Fibromyalgia, Partial-Onset Seizures, and More
Recarbrio Should be Reserved For Limited/No Alternative Antibacterial Treatment Cases
Patient Access to Inhaler Use Data Could Improve Asthma Management
Primary Immunodeficiencies Affect 250,000 People in U.S.
More Than 25% of Patients Responded to Xpovio/Dexamethasone Combo
Dupilumab Also Reduces Need for Polyp Surgery and Steroids
Patients Had Improved Lung Function, Fewer Exacerbations
Specific Monoclonal Antibodies Ensure Extreme Sensitivity, Accuracy
Almost 64% of Patients Showed Decreased Hemoglobin A1c Levels
Over Half of Patients Had Reduced Pain Levels of 30% or More
Over 25% of Study Patients Showed 6–12 Months Remission
First Anti-PD-1 Therapy Demonstrates Improved Overall Survival
Nexus Has Increased Power, RF Capabilities
New Indication for Ceftolozane/Tazobactam Injection
FDA Approves Combination Treatment for Relapsed/Refractory NHL
Only FDA-Approved Therapy for GVHD in Adults and Children